NCT02854761View on ClinicalTrials.gov

Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)

PHASE1UnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2018

Conditions
Recurrent Respiratory Papillomatosis
Interventions
DRUG

EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)

Sponsors

Lead Sponsor

Efranat Ltd.
All Listed Sponsors
lead

Efranat Ltd.

INDUSTRY